Article
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
Clinical pharmacokinetics - 1 Oct 2018
de Man Femke M, Goey Andrew K L, van Schaik Ron H N, Mathijssen Ron H J, Bins Sander
Abstract excerpt
Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung cancer. Irinotecan therapy is characterized by several dose-limiting toxicities and large interindividual pharmacokinetic variability. Irinotecan has a highly complex metabolism, including hydrolyzation by carboxylesterases to its...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.